Welcome to our dedicated page for CEL-SCI news (Ticker: CVM), a resource for investors and traders seeking the latest updates and insights on CEL-SCI stock.
CEL-SCI Corp (CVM) is a clinical-stage biotechnology leader advancing innovative immunotherapies for cancer, infectious diseases, and autoimmune conditions. This page provides investors and researchers with timely updates on the company’s clinical trials, regulatory milestones, and strategic initiatives.
Access authoritative reporting on Multikine Phase 3 head and neck cancer trials, LEAPS platform developments, and collaborative research with institutions like the University of Georgia. Our curated news collection ensures you stay informed about material events influencing CEL-SCI’s scientific and operational trajectory.
Key updates include treatment efficacy data, FDA communications, intellectual property advancements, and partnership announcements. All content is rigorously verified to provide actionable insights for stakeholders monitoring immunotherapy innovations.
Bookmark this page for streamlined access to CEL-SCI’s latest developments. Check regularly for unbiased reporting on breakthroughs that shape the future of immune-based therapies.
CEL-SCI has received FDA approval for a confirmatory study of its cancer immunotherapy Multikine for head and neck cancer patients, based on strong Phase 3 data showing a 73% survival rate with Multikine. The study will enroll 212 patients and aims to confirm the results of the Phase 3 trial, paving the way for potential approval. The FDA acknowledged the unmet need for improved therapies in this patient population, supporting approval for Multikine.
FAQ
What is the current stock price of CEL-SCI (CVM)?
What is the market cap of CEL-SCI (CVM)?
